Skip to content

Caudal Versus Intravenous Dexmedetomidine for Caudal Analgesia in Children

Caudal Versus Intravenous Dexmedetomidine for Caudal Analgesia in Children: A Randomised Controlled Double Blind Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02416063
Enrollment
75
Registered
2015-04-14
Start date
2014-01-31
Completion date
2014-10-31
Last updated
2015-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

The aim of this prospective randomized double-blind study was to compare the analgesic efficacy and the side effects of dexmedetomidine (1 µg.kg-1) co-administered with bupivacaine for caudal analgesia or intravenously in children undergoing infra-umbilical surgery.

Detailed description

Dexmedetomidine is used increasingly in pediatric anesthesia practice to prolong the duration of action of caudal block with a local anesthetic agent.But which route of administration of dexmedetomidine is the most beneficial remains unknown. The investigators performed prospective randomized double-blind study to compare the effects of caudal dexmedetomidine with intravenous dexmedetomidine on postoperative analgesia after caudal bupivacaine in children undergoing infra-umbilical surgery. 75 children (ASAⅠorⅡ,aged 1-6 yr) undergoing infra-umbilical surgery were included in this study. Anesthesia was induced with sevoflurane via a facemask, followed by placement of a laryngeal mask airway. Anesthesia was maintained with sevoflurane 2-3% in oxygen-air.Then,caudal block was applied. Patients were randomly assigned in three groups. Group B-Dcau (n = 25): Caudal bupivacaine 0.25% 1ml/kg plus dexmedetomidine 1µg/kg and 10 ml normal saline i.v.;Group B-Div (n = 25): bupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg(10 ml)i.v.;Group B(n = 25): bupivacaine 0.25% and 10 ml normal saline intravenous

Interventions

Drug:Caudal bupivacaine 0.25% 1ml/kg Drug: Caudal dexmedetomidine 1µg/kg Intravenous: 10 ml normal saline sevoflurane Induction and maintenance of anesthesia

Drug:Caudal bupivacaine 0.25% 1ml/kg. Drug:Intravenous dexmedetomidine1 μg /kg in a total volume of 10 ml sevoflurane Induction and maintenance of anesthesia

DRUGPlacebo

Drug:Caudal bupivacaine 0.25% 1ml/kg Intravenous: Normal saline 10 ml sevoflurane Induction and maintenance of anesthesia

Sponsors

University of Jordan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Years to 6 Years
Healthy volunteers
No

Inclusion criteria

* Patients with American Society of Anesthesiologists (ASA) - I * Scheduled for lower abdominal and perineal surgery * Under general anesthesia

Exclusion criteria

* Hypersensitivity to any local anesthetics * Patient has history of allergy, intolerance, or reaction to dexmedetomidine * Infections at puncture sites * Bleeding diathesis * Preexisting neurological disease * Children with uncorrected cardiac lesions * Children with heart block

Design outcomes

Primary

MeasureTime frameDescription
Time to first analgesic requirement24 hoursTime to first rescue medication. The time from end of surgery to the first requirement of postoperative analgesia,pain score ≥4

Secondary

MeasureTime frameDescription
Sevoflurane concentration1 hourSevoflurane concentration required to maintain Bispectral Index (BIS) monitor reading between 40 and 60
Blood pressure Perioperative blood pressure readings2 hoursPerioperative blood pressure readings
Heart Rate2 hoursPerioperative heart rate readings
Postoperative behaviour scores2 hoursbehaviour score was recorded throughout the post-anesthesia care unit stay at 15-minute time intervals.
Postoperative pain scores24 hourspostoperative pain score will be assessed over 24 hours
Side effects24 hoursside effects including nausea, vomiting and urinary retention and lower limb weakness
the incidence of emergence agitation2 hoursParticipants will be followed for the duration of PACU stay, an expected average of 2 hours

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026